Episode 64: Will POLARIX Finally Spell Doom for R-CHOP?

Chadi invites a trio of lymphoma experts to weigh the importance of the POLARIX trial – which was presented at the ASH Annual Meeting and looked at frontline therapy for patients with DLBCL. Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, co-authored publication of the POLARIX study “Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma” in the New England Journal of Medicine and defends the its results with guests Liz Brem, MD, UC Irvine, and Daniel Landsburg, MD, University of Pennsylvania. Can polatuzumab vedotin supplant conventional R-CHOP as the standard of care for previously untreated DLBCL? As they work through the details of the study, the experts share whether they believe the data supports an immediate standard-of-care change or if more research is needed.Read the study published in NEJMhttps://www.nejm.org/doi/full/10.1056/NEJMoa2115304Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA